Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
Related Articles
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022
Anumana and AliveCor Collaborate to Advance ECG-AI Algorithms for Early Detection of Cardiac Diseases on Kardia Devices
Anumana announces collaboration with AliveCorJanuary 07, 2025
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG DataCAMBRIDGE, Mass, June 27, 2024 Anumana, a leading AI-driven health technology company…June 27, 2024
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022